we have seen this play out before with another product of ours. Praluent will most likely stay on the market but will come at a price. Experts are anticipating 10-20% royalties to be paid by Sanofi/Regeneron. Coupled with a slow uptake of Praluent we can expect a major reorganization announced shortly after the deal. Apparently Amgen has a great case and is willing to take this all the way. If our team is foolish enough to proceed we could very well lose everything. However, our team is posturing to see if Amgen will settle for less. Amgen is passionate about this case and looking to prove a point. They will try for 40% or higher in royalties. Should be an interesting outcome since our team already admitted to infringing on the patents but questioned their validity.